Welcome to our dedicated page for VISKASE HOLDINGS SEC filings (Ticker: ENZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viskase Holdings, Inc. (ENZN) filings document the issuer's completed transition from Enzon Pharmaceuticals, Inc. to Viskase Holdings, including material-event reports on the merger closing, name change, exchange offer for Series C Non-Convertible Redeemable Preferred Stock, and related capital-structure disclosures.
The company's 8-K records also cover governance and ownership matters, including a Section 382 Rights Agreement, changes in certifying accountant, officer appointments, and amendments to the credit agreement of Viskase Companies, LLC, a wholly owned subsidiary. Other recurring disclosure areas include shareholder voting matters, material agreements, operating and financial results, risk factors, and legacy clinical or regulatory disclosures.
Viskase Holdings, Inc. adopted a Section 382 tax benefits preservation plan and related rights agreement to help protect the value of its net operating loss carryforwards (NOLs). The Board declared a dividend of one purchase right for each share of common stock outstanding to holders of record on May 15, 2026.
Each right allows, under certain conditions, the purchase of one one-thousandth of a share of Series A-2 Junior Participating Preferred Stock at $30.00 per right. The plan is triggered if a holder’s beneficial ownership reaches 4.9% or more of the common stock (subject to grandfathering and exemptions), which is designed to reduce the risk of an “ownership change” that could limit use of NOLs. The rights plan generally expires on May 4, 2029, unless earlier redeemed, exchanged, terminated, or not approved by stockholders by May 4, 2027.
Viskase Holdings, Inc. announced that its wholly owned subsidiary Viskase Companies, LLC entered into a Seventh Amendment to its Credit Agreement, extending the debt maturity date from August 13, 2026 to August 13, 2027.
The amendment increases the Applicable Rate by 1.0 percentage point on revolving loans, term loans and letters of credit, adjusts the definition of Consolidated EBITDA for certain restructuring and transaction costs, and permits asset dispositions at the Osceola Facility and Chicago Property. The amended facility continues to include customary covenants, is guaranteed by material restricted subsidiaries (other than Brazilian subsidiaries), and is secured by substantially all assets other than real property.
Viskase Holdings, Inc., formerly Enzon Pharmaceuticals, Inc., completed its merger with Viskase Companies, Inc. and subsequently changed its corporate name. Following this transaction, the Audit Committee appointed Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with unanimous Board ratification, subject to completion of client acceptance procedures.
Grant Thornton previously served as Viskase’s auditor before the merger. As a result of the change, EisnerAmper LLP, Enzon’s prior auditor, was dismissed. EisnerAmper’s reports on the company’s 2024 and 2025 financial statements were unqualified, and the company reports no disagreements or reportable events with EisnerAmper during that period. The company also states it did not consult Grant Thornton on accounting or auditing matters before the appointment.
Viskase Holdings, Inc. has promoted long-time finance executive Michael Blecic to Chief Financial Officer, effective April 10, 2026. Blecic, age 57, has worked at the company’s subsidiary since 1995 and has served as Vice President, Chief Accounting Officer and Treasurer since February 2013, roles he will retain.
The interim Chief Financial Officer engagement with Mackenzie Stender through Silverman Consulting, Inc. ended as of the same date. Viskase also appointed Joseph D. King as Executive Vice President while he continues as Senior Vice President, General Counsel and Secretary. Neither Blecic nor King will receive additional compensation beyond normal annual merit increases for these new titles.
Viskase Holdings, Inc. reported insider ownership changes tied to a merger and reverse stock split, not open-market trading. An entity affiliated with Carl C. Icahn disposed of 39,277 shares of preferred stock in a transaction to the issuer, exchanged for 5,658,396 shares of common stock in connection with the merger of the company and Viskase Companies, Inc.
Additional common shares were received in the merger and adjusted for a 1-for-100 reverse stock split effected on March 25, 2026. Following these transactions, entities associated with Icahn indirectly held 13,426,451 shares of common stock through American Entertainment Properties Corp, with Icahn and related entities disclaiming beneficial ownership beyond any pecuniary interest.
Carl C. Icahn and affiliated entities report owning 13,426,451 shares of Viskase Holdings, Inc. common stock, representing 93.7% of the company’s 14,331,713 outstanding shares as of March 26, 2026. This amended Schedule 13D reflects changes tied to Viskase’s merger with Viskase Companies, Inc.
On March 25, 2026, the Icahn group exchanged 39,277 shares of preferred stock for 5,658,396 Viskase common shares under an IEH Support Agreement. On March 26, 2026, they received a further 7,407,489 Viskase shares in exchange for 150,810,078 Viskase Companies, Inc. shares at the merger closing. Three Icahn-affiliated executives—Robert Flint, Colin Kwak, and Dustin DeMaria—joined Viskase’s board of directors in connection with the merger.
Viskase Holdings, Inc. filed an initial insider ownership report for company officer Joseph D. King
Viskase Holdings, Inc. director Kenneth Shea filed an initial ownership report on Form 3 for the company’s stock. The filing lists him as a director of Viskase but shows no reportable transactions or derivative positions and no share counts in this data excerpt.
Viskase Holdings, Inc. reported that executive Armando Herrera Jr. filed an initial Form 3 as an officer of the company. The filing lists no stock transactions and shows no reported derivative positions or holdings in the provided data. This is a routine disclosure of insider status required under SEC rules.
Viskase Holdings, Inc. director Robert Flint has filed an initial statement of beneficial ownership on Form 3. This filing identifies him as a director of the company but, based on the available data, does not report any stock purchases, sales, option exercises, gifts, or other transactions.